Trials / Terminated
TerminatedNCT05140824
A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients With Systemic Lupus Erythematosus
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- TJ Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of TJ202 in Patients with Systemic Lupus Erythematosus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | 0.9% sodium chloride solution |
| BIOLOGICAL | TJ202 injection | TJ202 injection |
Timeline
- Start date
- 2021-12-30
- Primary completion
- 2022-12-14
- Completion
- 2022-12-14
- First posted
- 2021-12-01
- Last updated
- 2024-04-15
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05140824. Inclusion in this directory is not an endorsement.